NEW YORK, NY / ACCESSWIRE / April 2, 2018 / Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register with us free at http://rdinvesting.com and get exclusive access to our numerous research reports and market updates.

RDI has Initiated Coverage Today on:

Fennec Pharmaceuticals Inc.
https://rdinvesting.com/news/?ticker=FRX.TO

Aptose Biosciences Inc.
https://rdinvesting.com/news/?ticker=APS.TO

Oncolytics Biotech Inc.
https://rdinvesting.com/news/?ticker=ONC.TO

CardioComm Solutions, Inc.
https://rdinvesting.com/news/?ticker=EKG.V

Fennec Pharmaceuticals' stock moved 1.85% lower Thursday, to close the day at $15.36. The stock recorded a trading volume of 9,031 shares, which was above its three months average volume of 1,629 shares. In the last year, Fennec Pharmaceuticals' shares have traded in a range of 3.75 - 16.23. The share price has gained 309.60% from its 52 week low. The company's shares are currently trading above their 200-day moving average. The stock's 50-day moving average of $12.32 is below its 200-day moving average of $12.43. Shares of Fennec Pharmaceuticals have gained approximately 22.98 percent year-to-date.

Access RDI's Fennec Pharmaceuticals Inc. Research Report at:
https://rdinvesting.com/news/?ticker=FRX.TO

On Thursday, shares of Aptose Biosciences recorded a trading volume of 50,846 shares, which was below the three months average volume of 62,437 shares. The stock ended the day 7.69% higher at 4.06. The share price has gained 286.67% from its 52-week low with a 52-week trading range of 1.05 - 5.18. The company's shares are currently trading above their 200-day moving average. The stock's 50-day moving average of $4.03 is greater than its 200-day moving average of $2.88. Shares of Aptose Biosciences have gained approximately 46.04 percent year-to-date.

Access RDI's Aptose Biosciences Inc. Research Report at:
https://rdinvesting.com/news/?ticker=APS.TO

Oncolytics Biotech's stock moved 1.49% lower Thursday, to close the day at $0.66. The stock recorded a trading volume of 25,395 shares, which was below its three months average volume of 330,624 shares. In the last year, Oncolytics Biotech's shares have traded in a range of 0.42 - 1.13. The share price has gained 57.14% from its 52 week low. The company's shares are currently trading below their 200-day moving average. The stock's 50-day moving average of $0.72 is greater than its 200-day moving average of $0.70. Shares of Oncolytics Biotech have fallen approximately 7.04 percent year-to-date.

Access RDI's Oncolytics Biotech Inc. Research Report at:
https://rdinvesting.com/news/?ticker=ONC.TO

On Thursday, shares of CardioComm Solutions recorded a trading volume of 91,000 shares, which was below the three months average volume of 144,224 shares. The stock ended the day flat at 0.04. The stock is currently trading 65.38% below its 52-week high with a 52-week trading range of 0.05 - 0.13. The company's shares are currently trading below their 200-day moving average. The stock's 50-day moving average of $0.05 is below its 200-day moving average of $0.05.

Access RDI's CardioComm Solutions, Inc. Research Report at:
https://rdinvesting.com/news/?ticker=EKG.V

Our Actionable Research on Fennec Pharmaceuticals Inc. (TSX:FRX.TO), Aptose Biosciences Inc. (TSX:APS.TO), Oncolytics Biotech Inc. (TSX:ONC.TO) and CardioComm Solutions, Inc. (TSXV:EKG.V) can be downloaded free of charge at Research Driven Investing.

Research Driven Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker-dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com